Zhejiang Zhenyuan ademetionine succinate is expected to obtain production approval in the first half of the year

Zhou Qianli, a secretary of the board of directors of Zhenyuan, Zhejiang Province, said at the strategic meeting of securities companies that the company's new drug for liver and gall, ademetionine succinate API and injection, is expected to obtain production approval in the first half of the year On March 20, the status of the new drug changed to "under approval", and it is expected to get the production approval document in the second quarter, when it will share the domestic market with Abbott and Haizheng pharmaceutical According to the official website of Zhenyuan Pharmaceutical Co., Ltd., a subsidiary of Zhejiang Zhenyuan, ademetionine succinate was developed by the company in 2004 Up to now, the company has invested tens of millions of yuan in R & D and supporting production equipment system costs If it is approved for listing, it is likely to become a major new strategic product Data show that adenosylmethionine is a kind of physiologically active molecule commonly existing in human tissues and body fluids, which is mainly suitable for intrahepatic cholestasis and intrahepatic cholestasis in pregnancy before and after cirrhosis, and can make the abnormal liver function caused by various reasons turn to normal It is reported that adenosylmethionine succinate, the first pharmaceutical imitator of Haizheng pharmaceutical, achieved a revenue of more than 100 million yuan in the first half of 2013.